HC Wainwright Estimates Verastem’s Q1 Earnings (NASDAQ:VSTM)

Verastem, Inc. (NASDAQ:VSTM) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Verastem in a research report issued on Monday, March 24th. HC Wainwright analyst S. Lee anticipates that the biopharmaceutical company will post earnings per share of ($0.67) for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Verastem’s current full-year earnings is ($3.02) per share. HC Wainwright also issued estimates for Verastem’s Q2 2025 earnings at ($0.74) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.62) EPS, FY2026 earnings at ($1.10) EPS and FY2027 earnings at ($0.33) EPS.

Several other analysts have also commented on the stock. StockNews.com raised shares of Verastem from a “sell” rating to a “hold” rating in a research note on Monday, March 24th. Guggenheim raised their price objective on Verastem from $13.00 to $14.00 and gave the stock a “buy” rating in a research note on Monday, March 24th. Mizuho boosted their target price on Verastem from $7.00 to $9.00 and gave the stock an “outperform” rating in a research report on Thursday, December 19th. Royal Bank of Canada decreased their price target on Verastem from $16.00 to $14.00 and set an “outperform” rating for the company in a research report on Friday, March 21st. Finally, BTIG Research lifted their price target on Verastem from $13.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, December 31st. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $13.88.

Verastem Stock Performance

NASDAQ:VSTM opened at $6.19 on Thursday. The company has a 50-day moving average of $6.14 and a 200-day moving average of $4.76. The firm has a market cap of $318.70 million, a price-to-earnings ratio of -1.94 and a beta of 0.60. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 2.77. Verastem has a twelve month low of $2.10 and a twelve month high of $13.52.

Verastem (NASDAQ:VSTM) last announced its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.57).

Institutional Trading of Verastem

A number of hedge funds have recently made changes to their positions in VSTM. Tower Research Capital LLC TRC increased its stake in Verastem by 51.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,997 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 1,698 shares during the period. FMR LLC purchased a new stake in shares of Verastem during the third quarter worth $41,000. JPMorgan Chase & Co. raised its holdings in shares of Verastem by 55.4% during the third quarter. JPMorgan Chase & Co. now owns 16,878 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 6,016 shares in the last quarter. ProShare Advisors LLC acquired a new stake in Verastem during the fourth quarter valued at $56,000. Finally, Voya Investment Management LLC purchased a new position in Verastem in the fourth quarter valued at about $59,000. 88.37% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Verastem

In other Verastem news, CEO Dan Paterson sold 8,568 shares of the firm’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $5.24, for a total transaction of $44,896.32. Following the completion of the sale, the chief executive officer now directly owns 347,581 shares in the company, valued at approximately $1,821,324.44. This trade represents a 2.41 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last ninety days, insiders have sold 9,960 shares of company stock valued at $53,498. Company insiders own 2.20% of the company’s stock.

About Verastem

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.